Modification of HDL structure and function in individuals with diabetes and the haptoglobin 2-2 genotype

Bibliography

• Rader DJ: Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116, 3090–3100 (2006).
   Google Scholar
• Excellent review of HDL metabolism and function by one of the top figures in HDL biology
   Google Scholar
• Navab M, Ananthaaramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: proatherogenic HDL — an evolving field. Nat. Clin. Pract. Endocrinol. Metab. 2, 504–511 (2006).
   Google Scholar
• Excellent review of the concept of HDL dysfunction
   Google Scholar
• Kontush A, Chapman MJ: Functionally defective high density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342–373 (2006)
   Google Scholar
• Ferretti G, Bacchetti T, Negre-Salvayre A, Salvayre R, Dousset N, Curatola G: Structural modifications of HDL and functional consequences. Atherosclerosis 184, 1–7 (2006)
   Google Scholar
• Norata GD, Pirillo A, Catapano AL: Modified HDL: biological and physiopathological consequences. Nutr. Metab. Cardiovasc. Dis. 16, 371–386 (2006)
   Google Scholar
• Watanabe J, Chou KJ, Liao JC et al.: Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. J. Biol. Chem. 282, 23698–23707 (2007)
   Google Scholar
• Groop FH, Thomas MC, Rosenbard-Barlund M et al.: HDL composition predicts new onset cardiovascular disease in patients with Type 1 diabetes. Diab. Care 30, 2706–2707 (2007)
   Google Scholar
• Wu Z, Wagner MA, Zheng L et al.: The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 14, 861–868 (2007).
   Google Scholar
• Original research paper describing the structural changes that are found in dysfunctional HDL focusing particularly on changes in the lecithin:cholesterol acyltransferase binding site
   Google Scholar
• Shao B, Oda MN, Vaiser T, Oram JF, Heinecke JW: Pathways for oxidation of high-density lipoprotein in human cardiovascular disease. Curr. Opin. Mol. Ther. 8, 198–205 (2006)
   Google Scholar
• Anantharamaiah GM, Mishra VK, Garber DW et al.: Structural requirements for antioxidant and anti-inflammatory properties of apolipoprotein A-1 mimetic peptides. J. Lipid Res. 48, 1915–1923 (2007)
   Google Scholar
• Shao B, Oda MN, Bergt C et al.: Myeloperoxidase impairs ABCA1- dependent efflux through methionine oxidation and site specific tyrosine chlorination of apolipoprotein A1. J. Biol. Chem. 281, 9001–9004 (2006)
   Google Scholar
• Blum CB, Levy RI, Eisenberg S, Hall M, Goebel RH, Berman M: High density lipoprotein metabolism in man. J. Clin. Invest. 60, 795–807 (1977)
   Google Scholar
• Nobecourt E, Davies MJ, Brown BE et al.: The impact of glycosylation on apolipoprotein A-1 structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50, 643–653 (2007)
   Google Scholar
• Alexander ET, Bhat S, Thomas MJ et al.: Apolipoprotein A-1 helix 6 negatively charged residues attenuate lecithincholesterol acyltransferase (LCAT) reactivity. Biochemistry 44, 5409–5419 (2005)
   Google Scholar
• HOPE and HOPE-TOO Trial Investigators: Effects of long-term vitamin E supplementation on cardiovascular events and cancer. JAMA 293, 1338–1347 (2005)
   Google Scholar
• The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Vitamin E supplementation and cardiovascular events in high risk patients. N. Engl. J. Med. 342, 154–160 (2000)
   Google Scholar
• Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high risk individuals; a randomized placebo controlled trial. Lancet 360, 7–22 (2002)
   Google Scholar
• Waters DD, Alderman EL, Hsia J et al.: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in post menopausal women: a randomized controlled trial. JAMA 288, 2432–2440 (2002)
   Google Scholar
• Collaborative Group of the Primary Prevention Project: Low dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357, 89–95 (2001)
   Google Scholar
• GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447–455 (1999)
   Google Scholar
• Stephens NG, Parsons A, Schofeld PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347, 781–786 (1996)
   Google Scholar
• Lee IM, Cook NR, Gaziano JM et al: Vitamin E in the primary prevention of cardiovascular disease and cancer. The Women’s Health Study: a randomized controlled trial. JAMA 294, 56–65 (2005)
   Google Scholar
• Brown BG, Crowley J: Is there any hope for vitamin E? JAMA 293, 1387–1390 (2005)
   Google Scholar
• Redberg RF: Vitamin E and cardiovascular health. JAMA 294, 107–109 (2005)
   Google Scholar
• Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105, 2107–2111 (2002)
   Google Scholar
• Asleh R, Blum S, Kalet-Litman S et al.: Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57, 2794–2800 (2008).
   Google Scholar
• Original research paper describing how the haptoglobin (Hp) protein modifies HDL structure and how vitamin E prevents HDL dysfunction in individuals with the Hp 2-2 genotype and diabetes mellitus (DM)
   Google Scholar
• Blum S, Milman U, Shapira C, Levy AP: Pharmagenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics 9, 989–991 (2008)
   Google Scholar
• Milman U, Blum S, Shapira C et al.: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both Type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective, double-blinded clinical trial. Art. Thromb. Vasc. Biol. 28, 341–347 (2008).
   Google Scholar
• Randomized placebo-controlled clinical trial showing vitamin E reduces cardiovascular disease in individuals with Type II DM and the Hp 2-2 genotype
   Google Scholar
• Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet. 12, 189–261 (1982)
   Google Scholar
• Frank M, Lache O, Enav B et al.: Structure/function ana lysis of the anti-oxidant properties of haptoglobin. Blood 98, 3693–3698 (2001)
   Google Scholar
• Miller YI, Altamentova SM, Shaklai N: Oxidation of low density lipoprotein by hemoglobin stems from a heme initiated globin radical: antioxidant role of haptoglobin. Biochemistry 36, 12189–12198 (1997)
   Google Scholar
• Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N: Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 43, 3899–3906 (2004)
   Google Scholar
• Vaiser T, Pennathur S, Green PS et al.: Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J. Clin. Invest. 117, 746–756 (2007)
   Google Scholar
• Spagnuolo MS, Cigliano L, D’Andrea LD, Pedone C, Abrescia P: Assignment of the binding site for haptoglobin on apolipoprotein A-1. J. Biol. Chem. 280, 1193–1198 (2005)
   Google Scholar
• Kunitake ST, Carilli CT, Lau K, Protter AA, Naya-Vigne J, Kane JP: Identification of proteins associated with apolipoprotein A-1 containing lipoproteins purified by selected-affinity immunoabsorbtion. Biochemistry 33, 1988–1993 (1994)
   Google Scholar
• Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JCM: Proteomic ana lysis of high density lipoprotein. Proteomics 6, 721–730 (2006)
   Google Scholar
• Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42, 1589–1600 (1996)
   Google Scholar
• Awadallah S, Hamad M: The prevalence of Type II diabetes mellitus is haptoglobin phenotype independent. Cytobios 101, 145–150 (2000)
   Google Scholar
• Levy AP, Hochberg I, Jablonski K et al.: Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: the Strong Heart Study. J. Am. Coll. Card. 40, 1984–1990 (2002)
   Google Scholar
• Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP: Haptoglobin genotype is predictive of major adverse cardiac events in the one year period after PTCA in individuals with diabetes. Diabetes Care 26, 2628–2631 (2003)
   Google Scholar
• Suleiman M, Aronson D, Asleh R et al.: Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 19, 2802-2806 (2005)
   Google Scholar
• Costacou T, Ferrell RE, Orchard TJ: Haptoglobin genotype: a determinant of cardiovascular complication risk in Type I diabetes. Diabetes 257, 1702–1706 (2008)
   Google Scholar
• Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108, 661–663 (2003)
   Google Scholar
• Asleh R, Miller-Lotan R, Aviram M et al.: Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99, 1419–1425 (2006)
   Google Scholar
• Levy AP, Gerstein H, Lotan R et al.: The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27, 2767 (2004)
   Google Scholar
• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 154–160 (2000).
   Google Scholar